Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Lutikizumab, Placebo of Lutikizumab
AbbVie Deutschland GmbH & Co. KG
Hidradenitis Suppurativa
1 trial -
Placebo for Risankizumab Solution for Injection 90 mg/mL, Risankizumab, ABBV-066
AbbVie Deutschland GmbH & Co. KG
Psoriatic Arthritis
1 trial -
Placebo for risankizumab 300mg/3.33ml solution for infusion, ABBV-066 / Risankizumab, Placebo for Risankizumab 90mg/mL Solution for injection in Pre-filled Syringe, Risankizumab, ABBV-066, Risankizumab
AbbVie Deutschland GmbH & Co. KG
Crohn's Disease
1 trial -
Placebo for risankizumab, ABBV-066
AbbVie Deutschland GmbH & Co. KG
Crohn's disease
1 trial -
Prednisolon 1 mg JENAPHARM, Prednisolon 5 mg JENAPHARM, Prednisolone placebo-5mg, Prednisolon 20 mg JENAPHARM, Prednisolone placebo-10mg, Prednisolon 10 mg JENAPHARM, Upadacitinib placebo, Upadacitinib, Prednisolone placebo-20mg, Prednisolone placebo-1mg, Upadacitinib
AbbVie Deutschland GmbH & Co. KG
Giant Cell Arteritis
1 trial -
Risankizumab, Placebo for Risankizumab Solution for injection in prefilled syringe, ABBV-066
AbbVie Deutschland GmbH & Co. KG
Psoriatic Arthritis
1 trial -
Risankizumab, Risankizumab placebo solution for infusion, ABBV-066 / Risankizumab, ABBV-066, Risankizumab placebo solution for injection in pre-filled syringe, Risankizumab
AbbVie Deutschland GmbH & Co. KG
Ulcerative Colitis
1 trial -
Telisotuzumab Vedotin, DOCETAXEL
AbbVie Deutschland GmbH & Co. KG
c-Met overexpressing EGFR wildtype non-squamous non-small cell lung cancer
1 trial -
Timolol vehicle, Bimatoprost SR sham applicator, Timolol, Bimatoprost SR, Bimatoprost SR
AbbVie Deutschland GmbH & Co. KG
Ocular hypertension, Open-angle glaucoma
1 trial -
Truxima 500 mg concentrate for solution for infusion, Cyclophosphamide Injection 500 mg., Epcoritamab (GEN3013), Vincristine Sulfate 1 mg/ml solution for injection, Doxorubicinhydrochlorid Bendalis 2 mg/ml InjektionslΓΆsung, Epcoritamab (GEN3013), Truxima 100 mg concentrate for solution for infusion, Prednisone Zentiva 5 mg compresse
AbbVie Deutschland GmbH & Co. KG
Diffuse Large B-Cell Lymphoma (DLBCL)
1 trial -
Upadacitinib Placebo, Upadacitinib
AbbVie Deutschland GmbH & Co. KG
non-segmental vitiligo
1 trial -
Upadacitinib Placebo, Upadacitinib, Upadacitinib
AbbVie Deutschland GmbH & Co. KG
Alopecia Areata
1 trial -
Upadacitinib, DUPILUMAB, Upadacitinib, Upadacitinib, Upadacitinib, Upadacitinib, DUPILUMAB
AbbVie Deutschland GmbH & Co. KG
Dermatitis atopic
1 trial -
Upadacitinib, Placebo for upadacitinib tablet, Upadacitinib, Upadacitinib
AbbVie Deutschland GmbH & Co. KG
Ulcerative Colitis
1 trial -
Upadacitinib, RoActemra 162 mg solution for injection in pre-filled syringe., RoActemra 162 mg solution for injection in pre-filled pen., Upadacitinib, RoActemra 20 mg/mL concentrate for solution for infusion
AbbVie Deutschland GmbH & Co. KG
juvenile idiopathic arthritis
1 trial -
Venetoclax, AZACITIDINE, Venetoclax, azacitidine, Venetoclax, azacitidine
AbbVie Deutschland GmbH & Co. KG
Acute Myeloid Leukemia in First Remission
1 trial -
Venetoclax, Venetoclax, Cytarabine 100 mg/ml Solution for Injection or Infusion, Matching Placebo for Venetoclax, Venetoclax
AbbVie Deutschland GmbH & Co. KG
Acute Myeloid Leukemia
1 trial -
Venetoclax, Venetoclax, Gazyvaro 1,000 mg concentrate for solution for infusion., Calquence 100 mg film-coated tablets, Venetoclax
AbbVie Deutschland GmbH & Co. KG
Chronic Lymphocytic Leukemia
1 trial -
Venetoclax, Venetoclax, Matching Placebo for Venetoclax, Venetoclax, AZACITIDINE
AbbVie Deutschland GmbH & Co. KG
Acute Myeloid Leukemia
1 trial -
Venetoclax, Venetoclax, Venetoclax, Vidaza 25 mg/ml powder for suspension for injection, Placebo Venetoclax/ABT-199/Film-coated tablet Oral Use
AbbVie Deutschland GmbH & Co. KG
Higher-Risk Myelodysplastic Syndrome
1 trial -
risankizumab placebo, Risankizumab, ABBV-066 / Risankizumab, ABBV-066
AbbVie Deutschland GmbH & Co. KG
Ulcerative Colitis
1 trial -
-, Pred Forte 10 mg/ml colirio en suspensiΓ³n
AbbVie Deutschland GmbH & Co. KG
platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers.
1 trial -
ABBV-066, Lutikizumab
AbbVie Deutschland GmbH & Co. KG
Psoriatic Arthritis
1 trial -
ABBV-066, Lutikizumab, ABBV-382, ABBV-066 / Risankizumab, ABBV-8736
AbbVie Deutschland GmbH & Co. KG
Moderate to Severe Crohnβs Disease
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources